Pulmonary disease as a risk factor for community-acquired pneumonia caused by multiple pathogens, including Streptococcus pneumoniae Source: Eur Respir J 2001; 18: Suppl. 33, 502s Year: 2001
The effect of macrolide-resistance on the outcome of patients hospitalized for streptococcus pneumoniae pneumonia Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management Year: 2015
Early mortality in patients with community-acquired pneumonia: causes and risk factors Source: Eur Respir J 2008; 32: 733-739 Year: 2008
Community-acquired pneumonia in Europe: causative pathogens and resistance patterns Source: Eur Respir J 2002; 20: 20S-27S Year: 2002
MRSA as a cause of lung infection including airway infection, community-acquired pneumonia and hospital-acquired pneumonia Source: Eur Respir J 2009; 34: 1470-1476 Year: 2009
Peculiarities of community-acquired pneumonia course, caused by multiresistant strains of S. pneumoniae Source: Eur Respir J 2006; 28: Suppl. 50, 165s Year: 2006
Fast replicating strains of streptococcus pneumoniae are associated with severe community-acquired pneumonia Source: Annual Congress 2009 - Aetiology and treatment of community-acquired pneumonia Year: 2009
Streptococcus pneumoniae is the main causative agent of community-acquired pneumonia Source: Eur Respir J 2002; 20: Suppl. 38, 608s Year: 2002
Streptococcus pneumoniae resistance pattern and its clinical implicationsSource: Annual Congress 2006 - PG1 - Respiratory infections: pneumonia/antibiotic resistance and clinical outcome of lower respiratory tract infections Year: 2006
Severe Chlamydia pneumoniae community-acquired pneumonia Source: Eur Respir J 2003; 22: Suppl. 45, 545s Year: 2003
Antibiotic resistance genotype trend and association with host clinical characteristics in respiratory isolates of streptococcus pneumoniae Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014
Incidence, characteristics and outcomes of patients with severe community acquired-MRSA pneumonia Source: Eur Respir J 2009; 34: 1148-1158 Year: 2009
Is Chlamydia pneumoniae an important pathogen in patients with community-acquired pneumonia? Source: Eur Respir J 2003; 21: 741-742 Year: 2003
MRSA as a cause of community-acquired pneumonia Source: Eur Respir J 2009; 34: 1013-1014 Year: 2009
Macrolide-resistant mycoplasma pneumoniae in respiratory tract infection and its clinical relevance Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections Year: 2016
Community-acquired pneumonia due to streptococcus pneumoniae in hospitalized patients – mortality predictors Source: Annual Congress 2008 - Lower respiratory tract infection: from outbreak to prognostic tests Year: 2008
Prevalence of atypical bacterial pathogens in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013
Monitoring of Mycoplasma pneumoniae and Chlamydia pneumoniae in young patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2001; 18: Suppl. 33, 140s Year: 2001
Diagnostic challenge in community-acquired pneumonia and hospital-acquired pneumonia: risk factors and diagnostic methods for methicillin resistant Staphylococcus aureus Source: Annual Congress 2006 - Methicillin resistant Staphylococcus aureus (MRSA): a real hospital-based pathogen? Year: 2006
Community-acquired pneumonia (CAP) caused by mycoplasma pneumoniae or chlamydophila pneumoniae in children: Are there reliable signs/symptoms for clinical diagnostics? Source: Annual Congress 2013 –The burden of respiratory infections in children Year: 2013